EGFR and non-small cell lung carcinoma: (Figure 5) demonstrated notable cytotoxicity against MCF-7 breast cancer cells (IC50 = 6.70 ± 1.02 μM) and A549 non-small cell lung cancer (NSCLC) cells (IC50 = 20.49 ± 2.7 μM), performing comparably or better than the standard EGFR inhibitor lapatinib.